CS-1008 (humanized anti-DR5 antibody) + gemcitabine
Phase 2Completed 2 views this week 0 watching💤 Quiet
Interest: 35/100
35
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Cancer
Conditions
Pancreatic Cancer
Trial Timeline
Aug 15, 2007 → Aug 20, 2010
NCT ID
NCT00521404About CS-1008 (humanized anti-DR5 antibody) + gemcitabine
CS-1008 (humanized anti-DR5 antibody) + gemcitabine is a phase 2 stage product being developed by Daiichi Sankyo for Pancreatic Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT00521404. Target conditions include Pancreatic Cancer.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Cancer were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
12
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00521404 | Phase 2 | Completed |
Competing Products
20 competing products in Pancreatic Cancer